The adrenomedullin gene encodes two potent hypotensive peptides, adrenomedu
llin and proadrenomedullin NH2-terminal 20 peptide. As with other vasoactiv
e peptides, the mast difficult challenge is to prove the physiological rele
vance of their recognized pathological and pharmacological actions and to e
stablish, against that physiological background their therapeutic potential
.